Prospective Ascertainment for Late Effects Among Cancer Survivors

This study is currently recruiting participants.
Verified March 2013 by Memorial Sloan-Kettering Cancer Center
Sponsor:
Information provided by (Responsible Party):
Memorial Sloan-Kettering Cancer Center
ClinicalTrials.gov Identifier:
NCT01667952
First received: August 15, 2012
Last updated: March 14, 2013
Last verified: March 2013
  Purpose

The purpose of this study is to establish a registry of cancer survivors.


Condition Intervention
Pediatric or Young Adult Cancer Survivors
Genetic: Family History Questionnaire (FHQ) and Saliva or blood samples

Study Type: Observational
Study Design: Observational Model: Family-Based
Time Perspective: Prospective
Official Title: Prospective Ascertainment for Late Effects Among Cancer Survivors

Resource links provided by NLM:


Further study details as provided by Memorial Sloan-Kettering Cancer Center:

Primary Outcome Measures:
  • establish a registry of DNA [ Time Frame: 4 years ] [ Designated as safety issue: No ]
    For the purpose of facilitating future genetic laboratory investigations of late effects among cancer survivors. Patients in the ALTFU Program are followed for secondary malignant neoplasms and other adverse outcomes (so-called "late effects") including cardiomyopathy, pulmonary fibrosis, cardiac valvular pathology, osteoporosis, and others. The following data will be ascertained from each study participant: (1) family history information will be ascertained using the Family History Questionnaire (Appendix A); and (2) saliva or blood samples for genetic analysis.


Biospecimen Retention:   Samples With DNA

Saliva or blood samples will be collected in the clinic at the time of a routine visit.


Estimated Enrollment: 1000
Study Start Date: August 2012
Estimated Study Completion Date: August 2016
Estimated Primary Completion Date: August 2016 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Cancer Survivors
The purpose of this study is to establish a registry of cancer survivors. The registry will include detailed family history and germline DNA. Ultimately, we hope to improve our understanding of genetic susceptibility to secondary malignant neoplasms and other late effects among cancer survivors.
Genetic: Family History Questionnaire (FHQ) and Saliva or blood samples

Consented subjects will be given the Family History Questionnaire (FHQ) (Appendix A), to complete either in clinic or at home. Saliva or blood samples will be collected in the clinic at the time of a routine visit.

The patient will decide which type of sample they would like to donate.


  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients from the Adult Long-Term Follow-Up Program or Lymphoma Service will be recruited at a routine visit to MSKCC.

Criteria

Inclusion Criteria:

  • 18 years or older
  • English speaking
  • A personal history of pediatric or young adult cancer
  • Followed in the Adult Long-Term Follow-Up Program or Lymphoma Service at MSKCC

Exclusion Criteria:

  • Evidence of active progression of disease or recurrence
  • Neurocognitive deficits that impair ability to give informed consent.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01667952

Contacts
Contact: Emily Tonorezos, MD, MPH 646-888-4730
Contact: Ken Offit, MD 646-888-4050

Locations
United States, New York
Memorial Sloan Kettering Cancer Center Recruiting
New York, New York, United States, 10065
Contact: Emily Tonorezos, MD,MPH     646-888-4730        
Contact: Kenneth Offit, MD     646-888-4050        
Principal Investigator: Emily Tonorezos, MD, MPH            
Sponsors and Collaborators
Memorial Sloan-Kettering Cancer Center
Investigators
Principal Investigator: Emily Tonorezos, MD, MPH Memorial Sloan-Kettering Cancer Center
  More Information

Additional Information:
No publications provided

Responsible Party: Memorial Sloan-Kettering Cancer Center
ClinicalTrials.gov Identifier: NCT01667952     History of Changes
Other Study ID Numbers: 12-143
Study First Received: August 15, 2012
Last Updated: March 14, 2013
Health Authority: United States: Institutional Review Board

Keywords provided by Memorial Sloan-Kettering Cancer Center:
Family History Questionnaire (FHQ)
Blood sample
Salvia sample
12-145

ClinicalTrials.gov processed this record on May 21, 2013